Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant RecipientsAndrew H. Karaba, William A. Werbel, Dorry L. Segev et al.|medRxiv|2022Cited by 21
Predicting a Positive Antibody Response After 2 SARS-CoV-2 mRNA Vaccines in Transplant Recipients: A Machine Learning Approach With External ValidationJennifer L. Alejo, Sunjae Bae, Jonathan Mitchell et al.|Transplantation|2022Cited by 17
Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipientsElizabeth A. Thompson, Andrea L. Cox, Wabathi Ngecu et al.|JCI Insight|2023Cited by 11
Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipientsAlexandra T. Strauss, William A. Werbel, Amy Chang et al.|Liver Transplantation|2022Cited by 7
Letter to the editor: Six‐month antibody kinetics and durability in liver transplant recipients after two doses of SARS‐CoV‐2 mRNA vaccinationAmy Chang, Dorry L. Segev, Alexandra T. Strauss et al.|Hepatology Communications|2022Cited by 3